ResMed Inc (ASX:RMD)
A$ 38.15 -0.25 (-0.65%) Market Cap: 56.19 Bil Enterprise Value: 56.84 Bil PE Ratio: 32.77 PB Ratio: 6.99 GF Score: 96/100

Resmed Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 04:20PM GMT
Release Date Price: A$32.15
Chris Cooper
Goldman Sachs Group, Inc., Research Division - Research Analyst

Welcome, everyone. Thanks very much. Let's make a start. So thanks very much for coming. For the next session here, we have Rob Douglas, the COO of ResMed, and we're also joined by Amy Wakeham, the Chief Communications and Chief Investor Relations Officer, I believe, is a new title.

And for those who don't know me, I'm Chris Cooper, the health care analyst that covers ResMed here at Goldman Sachs. Rob, if you don't mind, let's just pass over to you just for a very brief introduction of yourself and to the company.

Robert A. Douglas
ResMed Inc. - President & COO

Yes. Thanks for coming. I'm Rob Douglas, President and Chief Operating Officer for ResMed. At ResMed, we're mostly known for our sleep apnea therapy business. Sleep apnea is a condition affecting early 1 billion patients around the world. And even though we've been going for over 30 years, we've only just got started really in finding and getting all those patients on treatment through the health care systems.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot